Nolato AB Class B ( (NLTBF) ) has released its Q1 earnings. Here is a breakdown of the information Nolato AB Class B presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nolato AB is a Swedish company specializing in the development and manufacturing of polymer-based products for various industries, including medical technology, pharmaceuticals, consumer electronics, telecom, automotive, and hygiene. The company operates globally with a focus on sustainability and innovation.
In its first-quarter report for 2025, Nolato AB reported strengthened earnings and a significant increase in its EBITA margin. The company’s sales totaled SEK 2,453 million, with an operating profit (EBITA) of SEK 271 million, reflecting an increase from the previous year. The EBITA margin improved to 11.0%, driven by strong performance in the Medical Solutions business area.
Key financial highlights include a profit after tax of SEK 199 million and earnings per share rising to SEK 0.74. The Medical Solutions segment saw a 2% increase in sales, adjusted for currency, contributing to a 1.9 percentage point rise in its EBITA margin. Engineered Solutions experienced a 3% decline in sales, but a favorable product mix and cost adjustments improved its EBITA margin to 10.1%.
Looking ahead, Nolato’s management remains optimistic about continuing its profitable growth journey, emphasizing innovation and sustainability. Despite geopolitical tensions, the company is well-positioned to support its customers with flexible production and strong financial health, aiming for long-term profitable growth.